Revelation Biosciences annual depreciation and amortization
2021
2022
2023
2024
2025
Revelation Biosciences Depreciation & Amortization Growth & History (REVB)
Revelation Biosciences's depreciation and amortization was $27,058 for fiscal 2025.
View full Revelation Biosciences company overviewRevelation Biosciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27,058 | −$865 | −3.10% |
| 2024 | 2024-12-31 | $27,923 | $2,874 | +11.47% |
| 2023 | 2023-12-31 | $25,049 | $1 | +0.00% |
| 2022 | 2022-12-31 | $25,048 | $8,266 | +49.26% |
| 2021 | 2021-12-31 | $16,782 | — | — |
Revelation Biosciences quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8,313 | $1,093 | +15.14% |
| Q1 2026 | 2026-03-31 | $7,203 | −$18 | −0.25% |
| Q4 2025 | 2025-12-31 | $5,852 | — | — |
| Q3 2025 | 2025-09-30 | $6,765 | −$455 | −6.30% |
| Q2 2025 | 2025-06-30 | $7,220 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $7,221 | $959 | +15.31% |
| Q3 2024 | 2024-09-30 | $7,220 | $958 | +15.30% |
| Q2 2024 | 2024-06-30 | $7,220 | $958 | +15.30% |
| Q1 2024 | 2024-03-31 | $6,262 | −$1 | −0.02% |
| Q3 2023 | 2023-09-30 | $6,262 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $6,262 | $0 | 0.00% |
| Q1 2023 | 2023-03-31 | $6,263 | $1 | +0.02% |
| Q3 2022 | 2022-09-30 | $6,262 | $191 | +3.15% |
| Q2 2022 | 2022-06-30 | $6,262 | $5,620 | +875.39% |
| Q1 2022 | 2022-03-31 | $6,262 | $5,620 | +875.39% |
| Q3 2021 | 2021-09-30 | $6,071 | — | — |
| Q2 2021 | 2021-06-30 | $642 | — | — |
| Q1 2021 | 2021-03-31 | $642 | — | — |
Revelation Biosciences depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Revelation Biosciences's depreciation and amortization increased from $16,782 to $27,058, a change of $10,276. The latest reported quarter, Q2 2026, shows $8,313.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Revelation Biosciences source filings ↗